Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Current Deferred Revenue (2022 - 2025)

Historic Current Deferred Revenue for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to $1.0 million.

  • Atara Biotherapeutics' Current Deferred Revenue fell 9913.1% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year decrease of 9913.1%. This contributed to the annual value of $95.1 million for FY2024, which is 2217.44% up from last year.
  • Atara Biotherapeutics' Current Deferred Revenue amounted to $1.0 million in Q3 2025, which was down 9913.1% from $1.6 million recorded in Q2 2025.
  • Atara Biotherapeutics' Current Deferred Revenue's 5-year high stood at $123.2 million during Q1 2024, with a 5-year trough of $1.0 million in Q3 2025.
  • For the 4-year period, Atara Biotherapeutics' Current Deferred Revenue averaged around $47.5 million, with its median value being $16.0 million (2025).
  • As far as peak fluctuations go, Atara Biotherapeutics' Current Deferred Revenue skyrocketed by 114097.14% in 2024, and later tumbled by 9913.1% in 2025.
  • Quarter analysis of 4 years shows Atara Biotherapeutics' Current Deferred Revenue stood at $85.0 million in 2022, then dropped by 8.43% to $77.8 million in 2023, then rose by 22.17% to $95.1 million in 2024, then plummeted by 98.94% to $1.0 million in 2025.
  • Its last three reported values are $1.0 million in Q3 2025, $1.6 million for Q2 2025, and $16.0 million during Q1 2025.